Bright Minds Biosciences ... (DRUG)
NASDAQ: DRUG
· Real-Time Price · USD
28.04
0.46 (1.67%)
At close: Jun 16, 2025, 3:59 PM
27.30
-2.64%
After-hours: Jun 16, 2025, 06:07 PM EDT
1.67% (1D)
| Bid | 26 |
| Market Cap | 198.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.06M |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | -200.29 |
| Forward PE | -7.29 |
| Analyst | Buy |
| Ask | 29.5 |
| Volume | 5,181 |
| Avg. Volume (20D) | 29,434 |
| Open | 28.29 |
| Previous Close | 27.58 |
| Day's Range | 27.57 - 28.40 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | 0.45 |
About DRUG
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DRUG
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DRUG stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
-1.24%
Bright Minds Biosciences shares are trading higher...
Unlock content with
Pro Subscription
7 months ago
+1.72%
Bright Minds Biosciences shares are trading higher after the company announced a collaboration with Firefly Neuroscience to provide a full analysis of the EEG data in the BREAKTHROUGH study.
2 months ago · seekingalpha.com
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2...